BATS · GSKH
Precidian ETFs Trust GSK plc
Financial Services · Asset Management
$69.88
Up+$0.98 (+1.43%)
Updated Aug 18, 2026, 3:55 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 694.47K
- P/E ratio
- —
- Dividend yield
- 1.13%
- 52-week range
- $68.25 – $82.02
- Volume
- 228.08
- Avg. volume
- 342
Price performance
GSKH price history
1M range · 21 trading sessions · Daily adjusted prices
GSKH closed at $69.88 after 21 trading sessions, up 0.46% for the selected period.
- Last close
- $69.88
- Period change
- +0.46%
- Period low
- $68.90
- Period high
- $75.40
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 17, 2026 | $69.64 | $69.8844 | $69.64 | $69.8844 | 228.08 |
| Aug 14, 2026 | $68.25 | $68.9018 | $68.25 | $68.9018 | 229.06 |
| Aug 13, 2026 | $69.56 | $69.8223 | $69.56 | $69.8223 | 223.06 |
| Aug 12, 2026 | $69.34 | $69.5921 | $69.34 | $69.5921 | 114 |
| Aug 11, 2026 | $71.79 | $71.79 | $70.3906 | $70.3906 | 108 |
| Aug 10, 2026 | $71.60 | $71.8846 | $71.60 | $71.8846 | 211 |
| Aug 7, 2026 | $73.10 | $73.2925 | $73.10 | $73.2925 | 213 |
| Aug 6, 2026 | $72.00 | $72.3149 | $72.00 | $72.3149 | 506 |
| Aug 5, 2026 | $71.33 | $71.4044 | $71.33 | $71.4044 | 220 |
| Aug 4, 2026 | $71.63 | $71.63 | $71.5353 | $71.5353 | 127.5 |
| Aug 3, 2026 | $72.05 | $72.05 | $71.06 | $71.3803 | 1.12K |
| Jul 31, 2026 | $71.75 | $71.75 | $71.6488 | $71.6488 | 125.8 |
| Jul 30, 2026 | $72.40 | $72.40 | $71.87 | $72.0255 | 644 |
| Jul 29, 2026 | $74.09 | $74.26 | $74.09 | $74.26 | 645 |
| Jul 28, 2026 | $76.73 | $77.72 | $75.40 | $75.40 | 1.43K |
| Jul 27, 2026 | $73.27 | $73.27 | $72.7499 | $72.7499 | 111.03 |
| Jul 24, 2026 | $72.00 | $72.00 | $71.55 | $71.9854 | 412 |
| Jul 23, 2026 | $70.56 | $71.0187 | $70.56 | $71.0187 | 114 |
| Jul 22, 2026 | $71.31 | $71.31 | $70.8349 | $70.8349 | 311 |
| Jul 21, 2026 | $70.31 | $71.05 | $70.31 | $70.847 | 313.06 |
| Jul 20, 2026 | $71.00 | $71.00 | $69.5661 | $69.5661 | 225 |
Latest GSKH news
The latest Smart Investors Daily articles mentioning GSKH.
Stock researchCompany · Overview
GSKH research
Overview
Company profile and research snapshot.
Company profile
The series, under normal circumstances, invests at least 95% of its net assets in American Depositary Receipts (“ADRs”) of GSK plc (the “Company”). The series will not invest directly in the company. The fund is non-diversified.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
